DSNKYDaiichi Sankyo Co., Ltd.

About Daiichi Sankyo Co., Ltd. (DSNKY)

Daiichi Sankyo Co., Ltd. (DSNKY) is a Drug Manufacturers - General company headquartered in Tokyo, Japan whose shares trade over-the-counter on the Pink tier.

Founded on September 28, 2005 through the merger of Daiichi Pharmaceutical and Sankyo, Daiichi Sankyo delivers innovative products that enhance the lives of millions of people around the world. Our recent successes include the antihypertensive agent olmesartan (Olmetec®), launched in 2002 by Sankyo and now available in more than 50 countries around the world; the antiplatelet agent prasugrel (Efient®), launched in 2009 for patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI); and edoxaban (Lixiana®), the first available factor Xa inhibitor in Japan, which launched in 2011 to help prevent venous thromboembolism (VTE).

DSNKY key facts

Ticker symbol

DSNKY

Market tier

Pink

Sector

Healthcare

Industry

Drug Manufacturers - General

Headquarters

Tokyo, Japan

Country of incorporation

JP

Estimated market cap

$44.47B (as of Apr 9, 2025)

Shares outstanding

1,916,602,000

Reporting standard

International Reporting: Tokyo Stock Exchange

Audit status

Audited

Fiscal year end

3/31

Daiichi Sankyo Co., Ltd. leadership

• Takashi Shoda — CEO

Explore more: Drug Manufacturers - General stocks · Healthcare sector · Pink stocks · OTC stocks starting with D